South Korea · Delayed Price · Currency is KRW Pharmicell Company Description
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally.
The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty.
The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug.
It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics.
Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 1968 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Hyun-Soo Kim |
Contact Details
Address: Ssangbong Building Seoul South Korea | |
| Phone | 82 2 3496 0114 |
Stock Details
| Ticker Symbol | 005690 |
| Exchange | Korea Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7005690003 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Hyun-Soo Kim | Chief Executive Officer and Chairman of the Board of Director |
| HeeCheol Jeong | MD, Internal Accounting Manager and Controller |
| Gil Su Jeong | MD, Head of Biomedical Division and Director |